Patents by Inventor Matthias Emanuel
Matthias Emanuel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11963946Abstract: A method of enhancing positive effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a serotonergic psychedelic in the same dosage form or administered as separate compositions within a combination treatment schedule. A method of enhancing positive effects of a psychedelic, by inducing the release of endogenous monoamines, and subsequently stimulating 5-HT2A receptors.Type: GrantFiled: April 22, 2021Date of Patent: April 23, 2024Assignee: Universitätsspital BaselInventor: Matthias Emanuel Liechti
-
Publication number: 20240115710Abstract: A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt.Type: ApplicationFiled: December 18, 2023Publication date: April 11, 2024Applicant: Mind Medicine, Inc.Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
-
Publication number: 20240090738Abstract: A dishwasher includes a tub at least partially defining a treating chamber, a rotatable spray arm comprising an outlet, and a liquid supply conduit fluidly coupled to the spray arm. A pump can be fluidly coupled to the liquid supply conduit and operated to flow liquid through an aperture in the liquid supply conduit and through the outlet in the rotatable spray arm.Type: ApplicationFiled: December 1, 2023Publication date: March 21, 2024Inventors: Matthias Emanuel Freiherr Von Andrian-Werburg, Veronica Marin Kramer, Miron Wawrzusiak
-
Patent number: 11896670Abstract: A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt.Type: GrantFiled: August 23, 2022Date of Patent: February 13, 2024Assignee: Mind Medicine, Inc.Inventors: Daniel Trachsel, Matthias Emanuel Liechti, Felix Lustenberger
-
Patent number: 11896181Abstract: A dishwasher and method of operating a dishwasher according to a cycle of operation are described herein. The dishwasher includes a tub at least partially defining a treating chamber, a rotatable spray arm comprising a nozzle outlet, and a liquid supply conduit fluidly coupled to the spray arm. A pump can be fluidly coupled to the liquid supply conduit and operated to flow liquid through an aperture in the liquid supply conduit.Type: GrantFiled: June 13, 2022Date of Patent: February 13, 2024Assignee: Whirlpool CorporationInventors: Matthias Emanuel Freiherr Von Andrian-Werburg, Veronica Marin Kramer, Miron Wawrzusiak
-
Patent number: 11861899Abstract: Systems and methods for displaying augmented reality content relative to an identified object are disclosed. The systems and methods can include a set of operations. An operation can include providing a first image. An operation can include determining interest points in the first image. An operation can include identifying an object in the first image. An operation can include identifying augmented reality content associated with the object. An operation can include determining a first transformation for displaying the augmented reality content in the first image relative to the identified object. An operation can include providing the interest points and the first transformation. An operation can include determining a second transformation for displaying the augmented reality content in a second image relative to the identified object using, at least in part, the first transformation and the interest points. An operation can include displaying, by a user device, the augmented reality content.Type: GrantFiled: November 22, 2019Date of Patent: January 2, 2024Assignee: Geenee GmbHInventors: Alexander Goldberg, Davide Mameli, Matthias Emanuel Thömmes, Andrii Tkachuk
-
Publication number: 20230414583Abstract: A composition of a compound represented generically by FIG. 1A for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIG. 1A to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating an individual, by administering a pharmaceutically effective amount of a compound of FIG. 1A to the individual and treating the individual.Type: ApplicationFiled: June 19, 2023Publication date: December 28, 2023Applicant: Mind Medicine, Inc.Inventors: Daniel TRACHSEL, Matthias Emanuel Liechti, Felix Lustenberger
-
Publication number: 20230397793Abstract: A dishwasher and method of operating a dishwasher according to a cycle of operation are described herein. The dishwasher includes a tub at least partially defining a treating chamber, a rotatable spray arm comprising a nozzle outlet, and a liquid supply conduit fluidly coupled to the spray arm. A pump can be fluidly coupled to the liquid supply conduit and operated to flow liquid through an aperture in the liquid supply conduit.Type: ApplicationFiled: June 13, 2022Publication date: December 14, 2023Inventors: Matthias Emanuel Freiherr Von Andrian-Werburg, Veronica Marin Kramer, Miron Wawrzusiak
-
Publication number: 20230355575Abstract: A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, especially in substance-assisted psychotherapy, by administering proMDMA or a proMDMA-like compound to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA or an MDMA-like substance and thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment and administering proMDMA or a proMDMA-like substance to the individual. A method of reducing abuse of MDMA, by administering proMDMA or a proMDMA-like substance, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse.Type: ApplicationFiled: May 16, 2023Publication date: November 9, 2023Applicant: Mind Medicine, Inc.Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
-
Patent number: 11801256Abstract: A method of enhancing positive effects of a psychedelic, by pretreating an individual with an antidepressant, administering a psychedelic to the individual, and inducing a more positive psychological state in the individual with the antidepressant-psychedelic combination compared with the psychedelic alone. A method of enhancing positive effects of a psychedelic, by inhibiting serotonin transport in an individual, increasing levels of endogenous monoamines in the individual, and stimulating 5-HT2A receptors in the individual. A composition including an antidepressant and a psychedelic in the same dosage form.Type: GrantFiled: March 10, 2022Date of Patent: October 31, 2023Assignee: Universitätsspital BaselInventors: Matthias Emanuel Liechti, Anna Margarete Becker
-
Publication number: 20230330085Abstract: Method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. Method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. Method of defining therapeutic doses of a psychedelic in clinical trials. Method of monitoring individuals for depression after treatment with LSD.Type: ApplicationFiled: June 16, 2023Publication date: October 19, 2023Applicant: Universitatsspital BaselInventors: Matthias Emanuel LIECHTI, Friederike Sophie HOLZE
-
Publication number: 20230285384Abstract: A method of dosing LSD in treating patients, by assessing genetic characteristics in the patient by identifying polymorphisms of CYP2D6 before use of a composition chosen from the group consisting of LSD, analogs thereof, derivatives thereof, and salts thereof, administering the composition to the patient based on the patient genetics, wherein a 50% dose is administered in a patient with non-functional CYP2D6 compared to a dose in functional CYP2D6 individuals, and producing maximum positive subjective acute effects in the patient and/or reducing anxiety and negative effects. A method of determining a preferred dose of LSD.Type: ApplicationFiled: May 22, 2023Publication date: September 14, 2023Applicant: Universitatsspital BaselInventors: Matthias Emanuel LIECHTI, Patrick Raphael VIZELI
-
Publication number: 20230285327Abstract: A composition of a compound represented by FIG. 1 for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIG. 1 to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating a patient having adverse reactions to psychedelics by administering a desoxyscaline derivative to the patient, and avoiding adverse effects present with psychedelics. A method of changing neurotransmission of an individual, by administering a desoxyscaline derivative, and changing neurotransmission in the individual.Type: ApplicationFiled: May 12, 2023Publication date: September 14, 2023Applicant: Mind Medicine, Inc.Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
-
Patent number: 11717517Abstract: A method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. A method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. A method of defining therapeutic doses of a psychedelic in clinical trials.Type: GrantFiled: April 8, 2021Date of Patent: August 8, 2023Assignee: Universitatsspital BaselInventors: Matthias Emanuel Liechti, Friederike Sophie Holze
-
Publication number: 20230233688Abstract: A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, by administering proMDMA, a proMDMA-like compound, or proR(-)MDMA to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA, an MDMA-like substance or R(-)MDMA thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics present that would not be suitable for MDMA treatment and administering proMDMA, a proMDMA-like substance, or proR(-)MDMA to the individual. A method of reducing abuse of MDMA, by administering proMDMA, a proMDMA-like substance, or proR(-)MDMA, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse.Type: ApplicationFiled: March 28, 2023Publication date: July 27, 2023Applicant: Mind Medicine, Inc.Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
-
Publication number: 20230227398Abstract: A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R? is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1 - C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Zallylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents.Type: ApplicationFiled: March 27, 2023Publication date: July 20, 2023Applicant: Mind Medicine, Inc.Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER
-
Publication number: 20230218568Abstract: A composition including R-MDMA, S-MDMA, or specific (not 1:1 as in racemic MDMA) combinations of these two enantiomers of racemic MDMA as well as R-MDA, S-MDA, and a combination that is not 1:1 of R-MDA and S-MDA. A method of treating an individual, especially in substance-assisted psychotherapy by administering the composition to the individual. A method of personalized medicine, by evaluating an individual who is in need of MDMA treatment and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment, and administering the composition to the individual. A method of reducing abuse of MDMA by an individual, by administering R-MDMA to the individual and thereby reducing abuse.Type: ApplicationFiled: December 14, 2022Publication date: July 13, 2023Applicant: UNIVERSITATSSPITAL BASELInventor: Matthias Emanuel LIECHTI
-
Publication number: 20230201160Abstract: A method of enhancing positive effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a serotonergic psychedelic in the same dosage form or administered as separate compositions within a combination treatment schedule. A method of enhancing positive effects of a psychedelic, by inducing the release of endogenous monoamines, and subsequently stimulating 5-HT2A receptors.Type: ApplicationFiled: March 6, 2023Publication date: June 29, 2023Applicant: UNIVERSITATSSPITAL BASELInventor: Matthias Emanuel LIECHTI
-
Publication number: 20230150906Abstract: A composition of a compound represented by FIG. 1 for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIG. 1 to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating a patient having adverse reactions to psychedelics by administering a desoxyscaline derivative to the patient, and avoiding adverse effects present with psychedelics. A method of changing neurotransmission of an individual, by administering a desoxyscaline derivative, and changing neurotransmission in the individual.Type: ApplicationFiled: November 16, 2022Publication date: May 18, 2023Applicant: Mind Medicine, Inc.Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL
-
Publication number: 20230091369Abstract: A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R? is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Z allylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents.Type: ApplicationFiled: November 28, 2022Publication date: March 23, 2023Applicant: Mind Medicine, Inc.Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER